OPTIMISE-CKD CEE: A Multinational, Observational, Secondary Data Study Describing Management and Treatment With Dapagliflozin in Routine Clinical Practice Among Patients With Chronic Kidney Disease in Central Eastern Europe
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Acronyms OPTIMISE-CKD CEE
- Sponsors AstraZeneca
Most Recent Events
- 06 Jun 2025 Planned number of patients changed from 1090 to 1086.
- 16 Jan 2024 New trial record